US biopharma giants, Pfizer and Amgen, along with South Korea’s Celltrion are emerging as frontrunners in the biosimilars race While Sandoz/Novartis can claim victory with the first FDA biosimilar approval of Zarxio in March, it’s Pfizer, Amgen and Celltrion that have the volume of biosimilars in the pipeline Amgen, Pfizer and Novartis are wisely … Continue reading Who’s Leading the Biosimilars Race?
Read morePrescribers, Pharmacists and Patients: Negotiating the Issues Around Biosimilars
With Zarxio’s entry into the U.S. market still pending, pharmacists need to be aware of biosimilars in order to better assist their patients. While the U.S.’s first approved biosimilar, Zarxio is yet to be available to prescribers and patients amid ongoing legal battles, the fact is that biosimilars will soon be a reality … Continue reading Prescribers, Pharmacists and Patients: Negotiating the Issues Around Biosimilars
Read more